信達生物(01801.HK)股價吐3.7% 擬折讓4.7%配新股兼遭主席減持
信達生物(01801.HK)擬折讓近4.7%配5,620萬股新股兼遭主席減持3,680萬股,該股連吐第二天,今天曾略失配股價50元,低見49.95元,現造50.5元,續吐3.7%,成交受市前兩宗合共3,680萬股P盤以每股50元上板帶動急增至5,260萬股,涉資26.38億元。
信達生物擬以每股50元(較昨天收市價折讓約4.7%),配售5,620萬股新股或佔擴大後股本4.02%,淨籌27.88億元。另外,公司主席兼首席執行官俞德超亦以同價配售3,680萬股,套現18.4億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.